[1] LI BJ, FRISTON K, MODY M, et al.A brain network model for depression: from symptom understanding to disease intervention[J]. CNS Neurosci Ther, 2018, 24(11): 1004-1019. [2] SILVERBERG ND, PANENKA WJ.Antidepressants for depression after concussion and traumatic brain injury are still best practice[J]. BMC Psychiatry, 2019, 19(1): 100-103. [3] BEYER C, CAPPETTA K, JOHNSON JA, et al.Meta-analysis: Risk of hyperhidrosis with second-generation antidepressants[J]. Depress Anxiety, 2017, 34(12): 1134-1146. [4] BLIER P.Neurotransmitter targeting in the treatment of depression[J]. J Clin Psychiatry, 2013, 74(2): 19-24. [5] HÖFLICH A, MICHENTHALER P, KASPER S, et al. Circuit mechanisms of reward, anhedonia, and depression[J]. Int J Neuropsychopharmacol, 2019, 22(2): 105-118. [6] PECIÑA M, SIKORA M, AVERY ET, et al. Striatal dopamine D2/3 receptor-mediated neurotransmission in major depression: Implications for anhedonia, anxiety and treatment response[J]. Eur Neuropsychopharmacol, 2017, 27(10): 977-986. [7] ROTOLO RA, PRESBY RE, TRACY O, et al.The novel atypical dopamine transport inhibitor CT-005404 has pro-motivational effects in neurochemical and inflammatory models of effort-based dysfunctions related to psychopathology[J]. Neuropharmacology. 2020, 18: 108325. [8] ZHAN P, WANG XS, LIU XY.Contemporary molecular targeted drug in the context of“precision medicine”: an attempting discussion of “precision drug design”[J]. Progress in Chemistry(化学进展), 2016, 9: 1363-1386. [9] DELGADO PL.Depression: the case for a monoamine deficiency[J]. J Clin Psychiatry, 2000, 61(6): 7-11. [10] HILLHOUSE TM, PORTER JH.A brief history of the development of antidepressant drugs: from mono-amines to glutamate[J]. Exp Clin Psychopharmacol, 2015, 23(1): 1-21. [11] BUNNEY WE JR, DAVIS JM.Norepinephrine in depressive reactions[J]. Arch Gen Psychiatry, 1965, 13(6): 483-494. [12] GRZELCZYK J, BUDRYN G, PEÑA-GARCÍA J, et al. Evaluation of the inhibition of monoamine oxidase a by bioactive coffee compounds protecting serotonin degradation[J]. Food Chem, 2021, 348: 129108-129119. [13] MONCHAUX DE OC, POURTAU L, VANCASSEL S, et al.Saffron extract-Induced improvement of depressive-like behavior in mice is associated with modulation of monoaminergic neurotransmission[J]. Nutrients, 2021, 13(3): 904-920. [14] LAUGHREN TP, GOBBURU J, TEMPLE RJ, et al.Vilazodone: clinical basis for the US Food and Drug Administration's approval of a new antidepressant[J]. J Clin Psychiatry, 2011, 72(9): 1166-1173. [15] EL MANSARI M, CRNIC A, OOSTERHOF C, et al.Long-term administration of the antidepressant vilazodone modulates rat brain monoaminergic systems[J]. Neuropharmacology, 2015, 99: 696-704. [16] LIM LW, JANSSEN ML, KOCABICAK E, et al.The antidepressant effects of ventromedial prefrontal cortex stimulation is associated with neural activation in the medial part of the subthalamic nucleus[J]. Behav Brain Res, 2015, 279: 17-21. [17] EL-MARASY SA, ELAWDAN SA, HASSAN A, et al.Anti-depressant effect of cerebrolysin in reserpine-induced depression in rats: behavioral, biochemical, molecular and immunohistochemical evidence[J]. Chem Biol Interact, 2021, 334: 109329. [18] QIAO YL, ZHOU JJ, LIANG JH, et al.Uncaria rhynchophylla ameliorates unpredictable chronic mild stress-induced depression in mice via activating 5-HT1A receptor: insights from transcriptomics[J]. Phytomedicine, 2021, 81: 153436. [19] CANALE V, KOTAŃSKA M, DZIUBINA A, et al. Design, sustainable synthesis and biological evaluation of a novel dual α2A/5-HT7 receptor antagonist with antidepressant-like properties[J]. Molecules, 2021, 26(13): 3828. [20] FOX ME, LOBO MK.The molecular and cellular mechanisms of depression: a focus on reward circuitry[J]. Mol Psychiatry, 2019, 24(12): 1798-1815. [21] ENGELHARD B, FINKELSTEIN J, COX J, et al.Specialized coding of sensory, motor and cognitive variables in VTA dopamine neurons[J]. Nature, 2019, 570: 509-513. [22] MUNZAR P, LAUFERT MD, KUTKAT SW, et al.Effects of various serotonin agonist, antagonist, and uptake inhibitors on the discrimininative stimulus effects of methamphetamine in rats[J]. J Pharmacol Exp Ther, 1999, 291(1): 239-250. [23] SUBHAN F, DESLANDES PN, PACHE DM, et al.Do antidepre-ssants affect motivation in conditioned place preference?[J]. European Journal of Pharmacology, 2000, 408(3): 257-263. [24] RECINELLA L, CHIAVAROLI A, FERRANTE C, et al.Effects of central RVD-hemopressin(α) administration on anxiety, feeding behavior and hypothalamic neuromodulators in the rat[J]. Pharmacol Rep, 2018, 70(4): 650-657. [25] OSSEWAARDE L, VERKES R, HERMANS E, et al.Two-week administration of the combined serotonin-noradrenaline reuptake inhibitor duloxetine augments functioning of mesolimbic incentive processing circuits[J]. Biol Psychiatry, 2011, 70(6): 568-574. [26] ZHANG Y, CUI XL, YANG P.Adverse drug reaction induced by antidepressants of SSRI and SNRI[J]. Chinese Journal of pharmacovigilance(中国药物警戒), 2010, 7(9): 554-556. [27] CALDARONE BJ, PATERSON NE, ZHOU J, et al.The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties[J]. The Journal of Pharmacology and Experimental Therapeutics, 2010, 335(3): 762-770. [28] SØRENSEN G, HUSUM H, BRENNUM LT, et al. Addiction-related effects of DOV 216,303 and cocaine: a comparative study in the mouse[J]. Basic & Clinical Pharmacology & Toxicology, 2014, 114(6): 451-459. [29] National Medical Products Administration. Guideline on the non-clinical investigation of the dependence potential of drugs[S].National Medical Products Administration, 2007. [30] Food and Drug Administration. Guidance for industry: assessment of abuse potential of drugs[S]. Food and Drug Administration, 2017. [31] European Medicines Agency.Guideline on the non-clinical investigation of the dependence potential of medicinal products[S]. European Medicines Agency, 2006. [32] ABBRUSCATO TJ, TRIPPIER PC.DARK classics in chemical neuroscience: methamphetamine[J]. ACS Chem Neurosci, 2018, 9(10): 2373-2378. |